A new methodology to predict the oncotype scores based on clinico-pathological data with similar tumor profiles
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A new methodology to predict the oncotype scores based on clinico-pathological data with similar tumor profiles
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-06
DOI
10.1007/s10549-023-07141-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Random forest-based prediction of stroke outcome
- (2021) Carlos Fernandez-Lozano et al. Scientific Reports
- Supervised machine learning model to predict oncotype DX risk category in patients over age 50
- (2021) Kate R. Pawloski et al. BREAST CANCER RESEARCH AND TREATMENT
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
- (2021) Kevin Kalinsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- RFDCR: Automated brain lesion segmentation using cascaded random forests with dense conditional random fields
- (2020) Gaoxiang Chen et al. NEUROIMAGE
- Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer
- (2020) Aline Baltres et al. Breast Cancer
- Generalized random forests
- (2019) Susan Athey et al. ANNALS OF STATISTICS
- Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data
- (2019) Amila Orucevic et al. BREAST
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx
- (2019) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Applying new Magee equations for predicting the Oncotype Dx recurrence score
- (2018) Maher Sughayer et al. Breast Cancer
- A predictive model for high/low risk group according to oncotype DX recurrence score using machine learning
- (2018) Isaac Kim et al. EJSO
- Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer
- (2016) Joan Albanell et al. EUROPEAN JOURNAL OF CANCER
- Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study
- (2015) B Yeo et al. BRITISH JOURNAL OF CANCER
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- (2015) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Probabilistic Forecasting
- (2014) Tilmann Gneiting et al. Annual Review of Statistics and Its Application
- Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
- (2013) Molly E Klein et al. MODERN PATHOLOGY
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- Histopathologic variables predict Oncotype DX™ Recurrence Score
- (2008) Melina B Flanagan et al. MODERN PATHOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started